ARCHIVES

In Brief: Wittes To Become Acting DCT Director; Kaufman Leaves NCI For Private Practice

This article is from The Cancer Letter archive.

Vol. 21 No. 07 | February 17, 1995

Download PDF Visit The Full Archive

Related Articles

Wyden, Schroeder Bill Would Require NIH To Test RU 486

October 23, 1992

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

Clinical Trials Approved By NCI CTEP Last Month

January 28, 2011

Regulatory Policy: Bush To Seek Legislation For Pediatric Drug Tests.

January 3, 2003

ODAC Votes 13:0 to Recommend Perjeta for Accelerated Approval

September 13, 2013

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

February 17, 1989